The BD FastImmune™ CD107a APC reagent is designed for the detection of degranulating T lymphocytes in activated whole blood and is intended for research use only. Applications include studies of cytotoxic CD8+ T-cell responses to viral and tumor antigens, correlation of T-cell cytolytic potential and cytokine expression, and live-cell sorting of functional antigen-specific CD8+ T cells. The CD107a detection assay can also be used as an alternative to 51Cr release assays.
Each vial supplies sufficient reagents for 50 stimulated samples and 50 unstimulated control samples. In performing the assay, 0.5 mL of whole blood is stimulated with antigen (not included) in the presence of two secretion inhibitors, monensin and brefeldin A (BFA), and CD107a antibody. For the unstimulated control, 0.5 mL of blood is treated with the secretion inhibitors and CD107a, but not antigen. Both blood samples are then stained for IFN-γ or other cytokine(s), as well as the gating markers CD3 and CD8 (not included).